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Recent advances have provided evidence that
prostaglandin E2 mediates the generation of fever in
response to interleukin-1 or lipopolysaccharide and
have reinforced the similarities of signaling
downstream of these two pyrogens.
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Fever — the elevation in body temperature in response to
disease — has interested both clinicians and cellular and
evolutionary biologists alike. It has been thoroughly estab-
lished that fever is an adaptive physiological response to
infection and that it serves a survival purpose in insects,
fish and various cold-blooded animals [1]. For warm-
blooded species, however, the advantage of fever is not
clear and, for humans, the case for any benefit from sus-
taining an elevated body temperature during an infection
is not convincing. Nevertheless, the febrile response
remains one of the most conserved — yet, until quite
recently, one of the least understood — biological reac-
tions to disease and measuring body temperature is the
earliest quantitative and the most frequent clinical assess-
ment in the home and in the hospital. 
As shown in Figure 1, the systemic response of fever is the
result of a cascade of events that begins with pathogenic
infection. In particular, infection with Gram-negative bac-
teria also results in the release of lipopolysaccharide
(LPS), a potent pyrogen, from the bacterial cell wall. In
addition to directly triggering endothelial cells of the
hypothalamus in the brain, LPS and other bacterial prod-
ucts can stimulate white blood cells to synthesize and
release cytokines — soluble proteins that regulate the
immune response. Some cytokines are endogenous activa-
tors of the hypothalamic thermoregulatory center thereby
initiating physiological mechanisms that result in fever. 
As the vast majority of infections occur outside the brain,
however, cytokines and bacterial products must somehow
trigger the hypothalamic neurons inside the brain [2]. The
key event at the hypothalamic–endothelial blood brain
barrier is the synthesis and release of prostaglandin E2
(PGE2) into the brain following exposure to pyrogenic
cytokines or bacterial LPS. PGE2 itself cannot stimulate
the hypothalamic neurons but instead induces the release
of the neurotransmitter cyclic AMP. The resulting effect of
pyrogens is to raise body temperature by raising the hypo-
thalamic temperature ‘set-point’ from the normal level
(which in humans is 36.5°C) to a higher level to produce
fever. A combination of heat conservation and heat produc-
tion in the peripheral tissues results in an increased body
temperature to match the elevated set-point. 
Fever and the study of LPS probably gave birth to the
field now known as cytokine biology, or at least the
biology of inflammatory cytokines. The link between
fever and cytokines was first made with the observation
that fever was associated with toxins from bacteria and
products of activated white blood cells (reviewed in [3]).
Although many years have passed since that initial obser-
vation, relatively little has been elucidated regarding the
physiological mechanism responsible for fever. The
biology of fever now appears to reach a near-final resolu-
tion following the targeted gene disruption of each of the
PGE2 receptors [4] and the identification of the signaling
component of the LPS receptor as a member of the inter-
leukin 1 (IL-1)-Toll-like receptor family [5]. As reported
by Ushikubi and colleagues [4], one of the specific PGE2
receptors termed EP3 is essential not only for
PGE2-induced fever but also for fever induced by IL-1β as
well as by LPS. This report puts to rest a long, unresolved
issue of whether fever-producing mechanisms require
PGE2 or whether there are other mediators of the central
nervous system that can raise the hypothalamic set-point.
A persistent, although even mild, elevation in body temp-
erature without an obvious cause is a worrisome concern
for the discerning patient and physician. The best ‘test’
that elevated body temperature is truly fever and an indi-
cator of the presence of disease is to administer an
antipyretic agent such as aspirin or acetaminophen, which
act by inhibiting cyclooxygenase, an enzyme involved in
PGE2 biosynthesis. Following this treatment, elevated
body temperature that is fever quickly falls whereas ele-
vated temperature that is not fever — and is therefore
hyperthermia due to excessive metabolic heat production
— is unaffected. Thus, the fundamental effect of inhibit-
ing the activity of cyclooxygenase is the decrease in PGE2
production and the reduction of the fever response. Clini-
cians rarely have doubted the essential role of inhibiting
PGE2 for reducing fever of any kind including hyper-
pyrexia (an extremely vigorous form of fever), but
researchers using rodent species have repeatedly raised
the issue of fever-inducing pathways that do not involve
PGE2. The report by Ushikubi and colleagues [4] has clar-
ified the field by providing unambiguous results on this
issue that are also consistent with years of previous studies
on the importance of PGE2 for fever production [6]. 
Ushikubi and co-workers [4] found that mice deficient in
EP3 do not develop fever following intracerebral injection
of PGE2 whereas mice deficient in the other specific
types of PGE2 receptor (EP1, EP2 and EP4) are still able
to develop fever. This experiment established that the
action of PGE2 in the brain requires the EP3 receptor.
Intracerebral administration of PGE2 is not a physiological
experiment, however, as it only mimics the fever caused
by a central nervous system hemorrhage where platelet-
derived PGE2 may play a role. So, what is a physiologi-
cally relevant experiment? Most fevers are derived from
peripheral infections. These infections stimulate the pro-
duction of cytokines from various cells but most com-
monly monocytes and neutrophils. Over 50 years ago,
these cytokines were called ‘granulocyte pyrogen’ or
‘endogenous pyrogen’ and in many ways initiated
cytokine research.
The biology of endogenous pyrogens was dominated by a
simple assay, that is, the ability to produce fever in an
animal, most commonly a rabbit. The working hypothesis
for production of fever was that endogenous pyrogen trav-
elled via the bloodstream to the hypothalamic thermoreg-
ulatory system where it triggered neurons to elevate the
temperature set-point. Exactly how the set-point was ele-
vated remained unclear until aspirin and other antipyretics
were shown to inhibit the synthesis of PGE2 [7], endoge-
nous pyrogens where shown to induce PGE2 production
[8] and PGE2 itself was shown to produce fever [9]. Thus,
a logical cascade of events emerged: infection stimulates
the production of endogenous pyrogen, which reaches the
hypothalamic area where it stimulates the synthesis of
PGE2; this is followed by PGE2-induced neuronal mecha-
nisms involving cyclic AMP [10] to elevate the tempera-
ture set-point, as previously mentioned. 
We now know that endogenous pyrogen, as originally pro-
posed by Beeson [11], is not a single substance. There are
several cytokines that produce fever upon intravenous
injection and hence each can be termed an endogenous
pyrogen. The most potent for humans and rabbits is IL-1β
(reviewed in [12]) but tumor necrosis factor α (TNFα)
and IL-6 are also endogenous pyrogens. In fact, there
seems to be a hierarchy in the production of these pyro-
gens in that TNFα induces IL-1β [13] and IL-1β induces
IL-6. In mice deficient in IL-6, IL-1β does not produce
fever (reviewed in [14]). It was therefore interesting to
determine whether IL-1β would produce fever in the
mice deficient in EP3. Following intravenous injection of
IL-1β, there was no fever in these mice compared with
mice deficient in EP1, EP2 and EP4 and with wild-type
mice. It was concluded that IL-1β induced PGE2 and that,
in the absence of EP3, there was no febrile response. This
conclusion was consistent with the cascade hypothesis
mentioned above.
But, as other cytokines are also pyrogenic, it was important
to test more than one endogenous pyrogen. To this end,
instead of injecting each of the pyrogenic cytokines,
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Figure 1
Scheme of the fever response. Most
infections trigger a febrile response by
stimulating monocytes to synthesize and
release several pyrogenic cytokines such as
IL-1, TNFα and IL-6. These enter the
circulation and reach the endothelial cells of
the hypothalamus. From these cells, PGE2 is
released into the brain and binds to EP3 on
cells in the hypothalamic thermoregulatory
center. PGE2 induces the release of cyclic
AMP (cAMP), which then acts to raise the
thermostatic set-point from normal levels to
elevated levels. The elevated set-point results
in mechanisms of peripheral heat conservation
(vasoconstriction) as well as increased
metabolic heat production until the
temperature of the blood that bathes the
hypothalamus matches the elevated set-point,
resulting in fever.
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Ushikubi and co-workers [4] tested the pyrogenicity of
LPS in the EP3-deficient mice. They assumed that LPS
would induce the synthesis of not only IL-1β but also
several other cytokines. Indeed, cells from mice lacking
EP3 produced IL-1β and IL-6 in vitro in response to LPS
but did not exhibit fever when injected intravenously with
LPS. With the assumption that LPS induces nearly all
pyrogenic cytokines — and indeed it does — the implica-
tion was that EP3 is required for mediating the fever not
only to IL-1β but also to all LPS-inducible cytokines,
including those chemokines (cytokine-related proteins)
that have been reported to cause PGE2-independent fever
(reviewed in [14]). The failure of EP3-deficient mice to
develop fever following LPS administration suggests that
all cytokines and chemokines of peripheral origin require
signaling by PGE2 for fever induction. To completely
resolve the possibility that chemokine-induced fever is
PGE2 independent, it needs to be demonstrated that
intracerebral injection of these chemokines does not
produce fever in EP3-deficient mice.
The story of LPS fever and EP3 does not stop there.
Clearly, the lack of a febrile response to LPS in EP3-defi-
cient mice also suggests that any direct action of LPS on
the hypothalamus, independent of the induction of
cytokines, also requires EP3. The requirement of EP3 for
mediating LPS-induced fever brings into account the
recent discovery that the signaling chain of the LPS recep-
tor is a member of the Toll-like receptor (TLR) family [5],
which contains proteins related to the primitive Drosophila
receptor-like molecule Toll. There are at least five TLRs
that are expressed in human cells [15] and function during
immune responses [16]. A region of the cytoplasmic
domain of the TLRs is homologous to a segment in the
IL-1 receptor type I cytoplasmic domain that is required
for IL-1 signaling [17]. 
As shown in Figure 2, the biological activity of LPS
depends on two non-signaling molecules: the constitutive
serum protein lipopolysaccharide-binding protein (LBP)
which binds to the lipid chains of LPS; and the mem-
brane protein CD14, to which LBP presents LPS [18].
Although CD14 does not have a cytoplasmic domain for
signal transduction, its expression is required for optimal
cell responses to LPS. In cells lacking CD14, the addition
of LBP does not restore the response to LPS but, in cells
expressing CD14, soluble LBP greatly enhances signal
transduction by LPS. The existence of a signaling chain
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Figure 2
PGE2 elevates the set-point of the
thermoregulatory center in the anterior
hypothalamus. Endothelial cells of the
blood–brain barrier recognize cytokines (for
example IL-1) or LPS by specific receptors; in
the case of IL-1 it is the IL-1 receptor type I
and in the case of LPS, it is Toll-like receptor-
2 (TLR-2). The cytoplasmic domain of the IL-1
receptor and TLR-2 contains a recognition
sequence (white circle) for the recruitment of
two intracellular proteins: MyD88 and the IL-1
receptor activating kinase (IRAK). The
recruitment of MyD88 and IRAK takes place
following the binding of LPS to TLR-2 and
initiates signal transduction, leading to the
release of arachidonic acid — the rate limiting
step in the synthesis of PGE2 by
cyclooxygenase. PGE2 then binds to the
type 3 PGE2 receptor (EP3) on glial cells
stimulating synthesis and release of cAMP.
The released cAMP acts as a neurotransmitter
and activates thermosensitive neurons to
increase the thermostatic set-point from
normothermic to fever levels.
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for LPS was proposed and, in fact, Lei and Morrison [19]
described a cell-surface receptor for LPS with a molecular
weight of 80,000. As TLR-2 has a similar molecular
weight, it is likely that TLR-2 is this 80,000 kDa LPS
receptor. Therefore, LBP binds to LPS and allows for the
coupling of TLR-2, resulting in limited signal transduc-
tion. Although the binding of LPS to TLR-2 is of very
low affinity (500–900 nM) [5], signaling is greatly
enhanced by the presence of CD14 at the membrane.
One can now envisage the optimal LPS signaling
complex to be TLR-2–LPS–CD14. Of related interest,
the LPS-resistant mouse strain C3H/HeJ has a mutation
in TLR-4 [20], suggesting that other TLRs may be
involved in LPS signaling.
The biological responses to LPS are often indistinguish-
able from those to IL-1 or TNFα. In terms of fever
research, a small amount (3 ng/kg) of LPS injected intra-
venously into rabbits produced a monophasic fever nearly
identical to that following an intravenous injection of
30 ng/kg of TNFα or IL-1β [21]. It could have easily
been predicted that cell signaling induced by LPS and
IL-1 or TNFα proceeded via very similar pathways. With
the present finding of TLR-2 as a signaling component
for LPS, the basis for the similarities to IL-1 signaling can
be understood. 
What is unresolved? The characteristic fever response to
intravenously injected IL-1β, TNFα, IL-6 or LPS is
rapid; in rabbits, the peak elevation of core temperature
occurs 50–60 minutes after injection and in mice at
20–25 minutes. Thus, the initiating event in the synthesis
of PGE2 for fever production must occur even earlier and
probably results in the rapid release of arachidonic acid,
the rate-limiting step in the synthesis of PGE2. Therefore,
to fit into the current understanding of the scheme, IL-1β,
IL-6, TNFα and LPS would each have to bring about the
rapid release of arachidonic acid from lipid precursors in
the cell membrane (see Figure 2). In fact, an increase in
PGE2 levels in the hypothalamic tissues surrounding the
thermoregulatory center has been found following IL-1β
and IL-6 treatment [22]. 
The signaling mechanism of IL-1β, IL-6, TNFα and LPS
that results in the release of arachidonic acid has not been
clearly demonstrated, however. In some cells, IL-1β will
induce the rapid release of phosphatidylcholine and dia-
cylglycerol from phospholipid precursors [23]. As diacyl-
glycerol contains arachidonic acid as one of its fatty acid
components, it could be a possible source of arachidonic
acid. Various neuronal stimuli have been described to acti-
vate phospholipase A2 and this may also lead to the gener-
ation of arachidonic acid. The main source of substrate for
rapid PGE2 synthesis in response to cytokines and LPS is
the key puzzle in this important field that remains to be
solved. We shall look forward to finding the solution.
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